Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV

Journal of Cellular Physiology

Volumn 204, Issue 2, 2005, Pages 687-692

  Geier, Mark S ^a,b   Tenikoff, Danik ^a,b   Yazbeck, Roger ^a,c   McCaughan, Geoffrey W ^d   Abbott, Catherine A ^c   Howarth, Gordon S ^a,b,c,e,f  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f CHILD HEALTH RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE I; GLUCAGON LIKE PEPTIDE 2; GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE DELETION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; INTESTINE INJURY; INTESTINE VILLUS; LABELING INDEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SMALL INTESTINE; STATISTICAL SIGNIFICANCE; TISSUE INJURY;

ANIMALS; ANTIGENS, CD26; BODY WEIGHT; COLITIS; COLON; DEXTRAN SULFATE; DISEASE PROGRESSION; GENE DELETION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SIZE; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 21644481903     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20333     Document Type: Article

References (38)

1. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. 2000. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267(20):6140-6150.
2. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. 2004. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 1679(1):18-28.
3. Boushey RP, Yusta B, Drucker DJ. 1999. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277(5 Pt. 1):E937-E947.
4. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, Schmidt M, Holst JJ, Hartmann B, Sangild PT. 2000. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 279(6):G1249-G1256.
5. Burrin DG, Petersen Y, Stoll B, Sangild P. 2001. Glucagon-like peptide 2: A nutrient-responsive gut growth factor. J Nutr 131(3):709-712.
6. Burrin DG, Stoll B, Guan X. 2003. Glucagon-like peptide 2 function in domestic animals. Domest Anim Endocrinol 24(2):103-122.
7. Chen T, Ajami K, McCaughan GW, Gorrell MD, Abbott CA. 2003. Dipeptidyl peptidase IV gene family. The DPIV family. Adv Exp Med Biol 524:79-86.
8. Drucker DJ. 2002a. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122(2):531-544.
9. Drucker DJ. 2002b. Gut adaptation and the glucagon-like peptides. Gut 50(3):428-435.
10. Drucker DJ. 2003. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17(2):161-171.
11. Drucker DJ, Erlich P, Asa SL, Brubaker PL. 1996. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93(15):7911-7916.
12. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. 1997. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15(7):673-677.
13. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. 1999. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276(1 Pt. 1):G79-G91.
14. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. 1995. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). J Biol Chem 270(23):14107-14114.
15. Farrell RJ, Peppercorn MA. 2002. Ulcerative colitis. Lancet 359(9303):331-340.
16. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. 2000a. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85(8):2884-2888.
17. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ. 2000b. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141(11):4013-4020.
18. Hendrickson BA, Gokhale R, Cho JH. 2002. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15(1):79-94.
19. Holst JJ, Deacon CF. 1998. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47(11):1663-1670.
20. Howarth GS, Xian CJ, Read LC. 1998. Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 33(2):180-190.
21. Howarth GS, Xian CJ, Read LC. 2000. Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors 18(2):119-133.
22. Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BP. 2003. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 102(5):1641-1648.
23. Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Scholmerich J, Ruschoff J. 2001. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Dis 16(4):238-246.
24. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Muller E, Rettig WJ, Gorrell MD. 1999. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 29(6):1768-1778.
25. MacDonald TT, Monteleone G, Pender SL. 2000. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51(1):2-9.
26. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. 2000. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97(12):6874-6879.
27. Mentlein R. 1999. Dipeptidyl-peptidase IV (CD26)-Role in the inactivation of regulatory peptides. Regul Pept 85(1):9-24.
28. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. 1993. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38(9):1722-1734.
29. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. 2003. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J 373(Pt. 1):179-189.
30. Renes IB, Verburg M, Van Nispen DJ, Taminiau JA, Buller HA, Dekker J, Einerhand AW. 2002. Epithelial proliferation, cell death, and gene expression in experimental colitis: Alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int J Colorectal Dis 17(5):317-326.
31. Rumi G, Tsubouchi R, Okayama M, Kato S, Mozsik G, Takeuchi K. 2004. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Dig Dis Sci 49(9):1466-1472.
32. Rutgeerts P. 2002. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 17(Suppl):S176-S185.
33. Scott RB, Kirk D, MacNaughton WK, Meddings JB. 1998. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 275(5 Pt. 1):G911-G921.
34. Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman ER, Jacobs DO, Zinner MJ, Ashley SW, Whang EE. 2000. Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteritis. J Surg Res 91(1):77-82.
35. Thulesen J, Hartmann B, Kissow H, Jeppesen PB, Orskov C, Holst JJ, Poulsen SS. 2001. Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal-jejunal transposition or small bowel resection. Dig Dis Sci 46(2):379-388.
36. Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. 2002. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 47(7):1447-1457.
37. Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF, Granger DN. 2004. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 49(4):556-564.
38. Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T. 2003. Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol 131(1):68-74.